NGM Biopharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:NGM Biopharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10849
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NGM Biopharmaceuticals Inc (NGM Bio) is a clinical-stage biopharmaceutical company that develops pipeline of biological therapeutics for the treatment of cardio-metabolic, immuno-oncology, retinal and liver diseases. The company’s pipeline products include NGM282, NGM386, NGM395, NGM621, NGM313, NGM217 and NGM120. Its NGM313 is an agonistic antibody of the beta-klotho pathway and development candidate for the treatment of metabolic conditions such as type 2 diabetes, obesity and non-alcoholic steatohepatitis. NGM Bio’s NGM282 is an engineered protein variant of FGF19 for the treatment of non-alcoholic steatohepatitis and bile acid-related diseases. The company’s biologics platform incorporates multiple technologies to generate and screen monoclonal antibodies. NGM Bio is headquartered in San Francisco, California, the US.

NGM Biopharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
NGM Biopharma Raises USD106 Million in Series E Financing 10
NGM Biopharmaceuticals Secures $36.8 Million Series D Financing 11
NGM Biopharma Raises USD20.7 Million in Series D Financing 12
NGM Biopharma Raises US$50 Million In Series C Venture Financing 13
Partnerships 14
NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 14
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 15
Daiichi Sankyo Enters Into Co-Development Agreement With NGM Biopharma For Diabetes Drugs 16
Licensing Agreements 17
Ablexis Enters into Licensing Agreement with NGM Biopharma 17
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 18
Equity Offering 19
NGM Biopharma Files Registration Statement to Raise up to USD75 Million IPO of Shares 19
NGM Biopharmaceuticals Inc – Key Competitors 20
NGM Biopharmaceuticals Inc – Key Employees 21
NGM Biopharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Corporate Communications 23
Oct 01, 2018: NGM Biopharmaceuticals names David J. Woodhouse as Chief Executive Officer and Aetna Wun Trombley as President and Chief Operating Officer 23
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NGM Biopharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
NGM Biopharma Raises USD106 Million in Series E Financing 10
NGM Biopharmaceuticals Secures $36.8 Million Series D Financing 11
NGM Biopharma Raises USD20.7 Million in Series D Financing 12
NGM Biopharma Raises US$50 Million In Series C Venture Financing 13
NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 14
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 15
Daiichi Sankyo Enters Into Co-Development Agreement With NGM Biopharma For Diabetes Drugs 16
Ablexis Enters into Licensing Agreement with NGM Biopharma 17
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 18
NGM Biopharma Files Registration Statement to Raise up to USD75 Million IPO of Shares 19
NGM Biopharmaceuticals Inc, Key Competitors 20
NGM Biopharmaceuticals Inc, Key Employees 21

List of Figures
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[NGM Biopharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Vitamin Shoppe Inc (VSI):企業の財務・戦略的SWOT分析
    Vitamin Shoppe Inc (VSI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Hewlett Packard Enterprise Company:戦略・SWOT・企業財務分析
    Hewlett Packard Enterprise Company - Strategy, SWOT and Corporate Finance Report Summary Hewlett Packard Enterprise Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Harpoon Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Harpoon Therapeutics Inc (Harpoon Therapeutics) is a biotechnology company that offers solutions for immune-oncology diseases. The company provides products portfolio such as of HPN424, prostate specific antigen and harnesses a technology named TriTAC technology. It employs TriTAC technology …
  • SpiceJet Limited:企業の戦略・SWOT・財務情報
    SpiceJet Limited - Strategy, SWOT and Corporate Finance Report Summary SpiceJet Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Syros Pharmaceuticals Inc (SYRS):企業の財務・戦略的SWOT分析
    Summary Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company’s pipeline products under clinical trials include SY-1425, an oral, potent and selective RARa agonist that is used t …
  • Edwards Lifesciences Corp (EW):企業の財務・戦略的SWOT分析
    Edwards Lifesciences Corp (EW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • NovoCure Ltd (NVCR):企業の製品パイプライン分析
    Summary NovoCure Ltd (NovoCure) develops and commercializes novel delivery systems for the treatment of cancers of brain, abdomen, and torso. Its proprietary Tumor Treating Fields (TTF) technology platform uses electric fields tuned to specific frequencies for disrupting the division solid tumor can …
  • Mitsubishi Tanabe Pharma Corp (4508):企業の財務・戦略的SWOT分析
    Mitsubishi Tanabe Pharma Corp (4508) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Koninklijke Vopak NV (VPK):石油・ガス:M&Aディール及び事業提携情報
    Summary Koninklijke Vopak NV (Vopak) is an independent tank storage company that stores and handles liquid oil products, chemicals, vegetable oils, biofuels and liquefied natural gases. It also offers logistics services, handles customs formalities and documentation for its customers at its terminal …
  • A&E Medical Corp:医療機器:M&Aディール及び事業提携情報
    Summary A&E Medical Corp (A&E Medical), a subsidiary of Vance Street Capital LLC, is a medical device company that manufactures and distributes surgical equipment. The company offers products such as temporary cardiac pacing wires, sternotomy sutures, lluminated vein harvest retractors, electrosurgi …
  • Pure Bioscience Inc (PURE):企業の財務・戦略的SWOT分析
    Pure Bioscience Inc (PURE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Sorgenia SpA:企業の戦略的SWOT分析
    Sorgenia SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Vedanta Resources Plc:企業の戦略・SWOT・財務分析
    Vedanta Resources Plc - Strategy, SWOT and Corporate Finance Report Summary Vedanta Resources Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Bristol-Myers Squibb Co (BMY):企業の財務・戦略的SWOT分析
    Bristol-Myers Squibb Co (BMY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Century Aluminum Co:企業の戦略・SWOT・財務情報
    Century Aluminum Co - Strategy, SWOT and Corporate Finance Report Summary Century Aluminum Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • MRF Ltd (MRF):企業の財務・戦略的SWOT分析
    MRF Ltd (MRF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Betta Pharmaceuticals Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Betta Pharmaceuticals Co Ltd (Betta Pharma) is a developer and manufacturer of drugs for treating cancer, cardiovascular diseases and diabetes. The company’s product includes conmana, a selective epidermal growth factor receptor tyrosine kinase inhibitor indicated for treating locally advanc …
  • Beacon Biomedical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Beacon Biomedical Inc (Beacon) is a medical diagnostic device company that offers point-of-care blood test systems. The company offers its product portfolio in the therapeutic areas of breast cancer, colorectal cancer and lung cancer. It holds two patented technologies such as signaling prot …
  • Progenics Pharmaceuticals, Inc.:企業の戦略・SWOT・財務分析
    Progenics Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report Summary Progenics Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Spanish National Cancer Research Center:製薬・医療:M&Aディール及び事業提携情報
    Summary Spanish National Cancer Research Center (CNIO) is a medical research center that conducts cancer research programs. The center integrates basic and translational cancer research. It conducts various scientific programs, which include molecular oncology program, structural biology and biocomp …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆